map

Our researchers are based all over europe

The PhD students will be based in 7 research groups in Europe. The training network is coordinated by the University of Leeds in the UK, where three students will be based. It is funded by a Marie Skłodowska-Curie Early Training Network (ETN) grant. Two students will be based at the Leiden University Medical Center in the Netherlands, three at the Universitåtsklinikum in Essen, Germany, three at Lunds Universitet in Sweden, two at the Genome Research Limited at the Wellcome Trust Sanger Institute in the UK, and two at the University of Oslo in Norway. Two students will be funded by the Swiss Government but as part of the ETN.

Find out more about our researchers

Project Co-Ordinator

The MELGEN training network is coordinated by the Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds. The Scientific Coordinator is Professor Julia Newton Bishop working with Dr Juliette Randerson Moor.

  • How does the body fight with melanoma?

    Here is a short (1min) and simplified video describing my project and some of the main results I have obtained so far. During my PhD, one of my research focus was to understand how melanoma can hide from the body’s defence mechanism, which is called the immune system. In my analyses,Read More
  • Understanding familial melanoma

      This is a brief video summarising my PhD project (ESR01) at the Wellcome Sanger Institute in Cambridge, UK.  It involves the sequencing and analysis of familial melanoma patients from across the world. To learn more, please read my blog post on the topic linked here. – Aravind Sankar (ESR01),Read More
  • Latest melanoma drug approvals: adjuvant dabrafenib plus trametinib

    New drug combination: adjuvant dabrafenib plus trametinib for BRAF-mutant stage III melanoma The European Commission approved the combination of dabrafenib plus trametinib (Tafinlar® and Mekinist® by Novartis) for the adjuvant therapy of complete surgically resected stage III melanoma patients with BRAFV600 mutation. The dual targeting of the hyper-activated MAPKRead More
  • Latest melanoma drug approvals: encorafenib plus binimetinib

    New drug combination: encorafenib plus binimetinib for BRAF-mutant metastatic melanoma Another milestone in the treatment of BRAFV600-mutant metastatic melanoma was marked by the newly approved drug combination of encorafenib plus binimetinib [Braftovi and Mektovi, by Array BioPharma Inc; approved by U.S. Food & Drug Administration (FDA) on June 27,Read More
  • MELGEN group leader Dr. David Adams elected as Fellow of the Academy of Medical Sciences

    Congratulations to Dr. David Adams for his well-deserved election to the Academy of Medical Sciences (F.Med.Sci). Dr. David Adams was elected as one of 48 Fellows to join the highly prestigious academy, which includes senior researchers and academics from across the medical sciences and industry. About the fellowship TheRead More
  • 15th Annual Joint GenoMEL/BioGenoMEL/MELGEN Scientific Meeting 2018

    From the 20th to the 22nd March 2018 the MELGEN Consortium joined forces with the GenoMEL and BioGenoMEL consortia to hold their annual scientific meeting, this year hosted by the University Hospital Essen in Germany. In contrast to last year’s sun and high temperatures, the start of this year’sRead More